We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+7.44%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$47B
AUM Growth
+$1.49B
(+3.3%)
Cap. Flow
-$1.29B
Cap. Flow
% of AUM
-2.74%
Top 10 Holdings %
Top 10 Hldgs %
15.27%
Holding
2,332
New
179
Increased
975
Reduced
1,019
Closed
154
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$229M |
| 2 |
McDonald's
MCD
|
+$150M |
| 3 |
McKesson
MCK
|
+$124M |
| 4 |
O'Reilly Automotive
ORLY
|
+$98.7M |
| 5 |
Booking.com
BKNG
|
+$87.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$209M |
| 2 |
NRG Energy
NRG
|
+$168M |
| 3 |
Microsoft
MSFT
|
+$167M |
| 4 |
Pfizer
PFE
|
+$155M |
| 5 |
TSMC
TSM
|
+$118M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.32% |
| 2 | Healthcare | 13.98% |
| 3 | Consumer Discretionary | 13.86% |
| 4 | Industrials | 12.56% |
| 5 | Financials | 9.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2051
Pliant Therapeutics
PLRX
$64.4M
| $225K | ﹤0.01% |
+12,434
| New | +$294K |
|
|
NAPA
2052
DELISTED
The Duckhorn Portfolio, Inc.
NAPA
| $224K | ﹤0.01% |
17,291
+954
| +6% | +$13.5K |
|
|
CLDT
2053
Chatham Lodging
CLDT
$573M
| $224K | ﹤0.01% |
23,887
+8,063
| +51% | +$79.8K |
|
|
CERE
2054
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $223K | ﹤0.01% |
7,021
-6,630
| -49% | -$203K |
|
2055
Gorman-Rupp
GRC
$2.18B
| $222K | ﹤0.01% |
7,716
-343
| -4% | -$8.74K |
|
2056
Johnson Outdoors
JOUT
$501M
| $222K | ﹤0.01% |
+3,617
| New | +$216K |
|
2057
Cytek Biosciences
CTKB
$568M
| $222K | ﹤0.01% |
+25,982
| New | +$233K |
|
2058
IMAX
IMAX
$2.8B
| $221K | ﹤0.01% |
+12,984
| New | +$246K |
|
2059
Twist Bioscience
TWST
$7.77B
| $219K | ﹤0.01% |
10,727
-1,202
| -10% | -$18K |
|
2060
Aldeyra Therapeutics
ALDX
$91.1M
| $219K | ﹤0.01% |
+26,158
| New | +$258K |
|
2061
Evolv Technologies
EVLV
$1.06B
| $218K | ﹤0.01% |
+36,414
| New | +$172K |
|
2062
Ocular Therapeutix
OCUL
$2.02B
| $218K | ﹤0.01% |
42,230
-288
| -0.7% | -$1.71K |
|
|
FRG
2063
DELISTED
Franchise Group, Inc.
FRG
| $218K | ﹤0.01% |
7,605
-855
| -10% | -$24.5K |
|
|
SILK
2064
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $218K | ﹤0.01% |
6,698
+500
| +8% | +$18.3K |
|
2065
Agios Pharmaceuticals
AGIO
$1.93B
| $217K | ﹤0.01% |
+7,717
| New | +$192K |
|
|
KYNB
2066
Kyntra Bio
KYNB
$28.7M
| $216K | ﹤0.01% |
3,196
+2,517
| +371% | +$1.04M |
|
2067
Materion
MTRN
$5.99B
| $214K | ﹤0.01% |
1,870
+36
| +2% | +$3.91K |
|
2068
Alcoa
AA
$13.5B
| $211K | ﹤0.01% |
+6,284
| New | +$228K |
|
2069
Krispy Kreme
DNUT
$551M
| $211K | ﹤0.01% |
14,299
+2,702
| +23% | +$40.5K |
|
2070
Rhythm Pharmaceuticals
RYTM
$7.96B
| $210K | ﹤0.01% |
+12,716
| New | +$230K |
|
|
CTLP
2071
DELISTED
Cantaloupe
CTLP
| $209K | ﹤0.01% |
26,270
-27,594
| -51% | -$179K |
|
2072
Enviri
NVRI
$618M
| $207K | ﹤0.01% |
20,946
-30,370
| -59% | -$250K |
|
2073
First Merchants
FRME
$2.66B
| $204K | ﹤0.01% |
+7,221
| New | +$205K |
|
2074
First Financial Bankshares
FFIN
$4.91B
| $202K | ﹤0.01% |
+7,086
| New | +$201K |
|
2075
WaFd
WAFD
$2.74B
| $201K | ﹤0.01% |
7,571
-613,513
| -99% | -$17M |
|
Similar funds
VGA
AQR Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, AQR Capital Management held 2,332 positions worth $47B, up 3.3% from $45.6B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
AQR Capital Management's Q2 2023 filing shows 179 new, 975 increased, 1,019 reduced and 154 closed positions. Its largest new stake was Vanguard Morningstar Total Stock Market ETF: 250,000 shares worth $55.1M. The largest sale was Intel, an estimated $209M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 22% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- AQR Capital Management's largest Q2 2023 buy was Vanguard Morningstar Total Stock Market ETF: 250,000 shares worth $55.1M.
- AQR Capital Management added most to NVIDIA in Q2 2023, an estimated $229M increase.
- AQR Capital Management's biggest Q2 2023 reduction was Intel, cutting an estimated $209M.
- AQR Capital Management fully exited Trip.com Group in Q2 2023, selling an estimated $29.2M.
- AQR Capital Management's ten largest holdings make up 15% of its $47B portfolio in Q2 2023.
- AQR Capital Management opened 179 new positions and closed 154 in Q2 2023.
- AQR Capital Management's portfolio value rose 3.3% quarter-over-quarter to $47B.
Based on AQR Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.